论文部分内容阅读
目的探讨贝那普利对糖尿病肾病尿微量白蛋白的影响。方法本实验选取在2011年2月份到2011年9月份到我院进行治疗的糖尿病肾病患者50例为研究对象,把所有患者随机分为25例观察组(贝那普利联合常规降糖治疗组)和25例对照组(常规降糖治疗组),后进行观察和统计治疗4周后、治疗12周后患者尿蛋白排泄率(UAE)的变化情况。结果两组患者在治疗4周后,两组UAE均开始降低,但差异无统计学意义(P>0.05);治疗12周后,治疗组UAE有明显降低,差异有统计学意义(P<0.01);两组患者在治疗4周和12周后,治疗组UAE降低情况明显优于对照组同期,差别有统计学意义(P<0.05)。结论贝那普利可以明显降低糖尿病肾病患者的尿微量白蛋白,效果显著、用药安全且无副作用,尤其适合用于肾功能不全的患者。
Objective To investigate the effect of benazepril on diabetic microalbuminuria in diabetic nephropathy. Methods Fifty patients with diabetic nephropathy who were treated in our hospital from February 2011 to September 2011 were enrolled in this study. All patients were randomly divided into 25 observation groups (benazepril combined with conventional hypoglycemic treatment group ) And 25 control group (conventional hypoglycemic treatment group). The changes of urinary protein excretion rate (UAE) after 12 weeks of treatment were observed and statistically treated for 4 weeks. Results After 4 weeks of treatment, the UAE in both groups began to decrease, but the difference was not statistically significant (P> 0.05). After 12 weeks of treatment, the UAE in the treatment group was significantly lower (P <0.01) ). After 4 weeks and 12 weeks of treatment, the reduction of UAE in the treatment group was significantly better than that in the control group, the difference was statistically significant (P <0.05). Conclusion Behenopril can significantly reduce urinary microalbuminuria in patients with diabetic nephropathy, the effect is significant, safe and no side effects, especially for patients with renal insufficiency.